• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

June 3, 2025
in Medical Research
Reading Time: 2 mins read
A A
0
ASCO: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
1
SHARES
3
VIEWS
Share on FacebookShare on Twitter


ASCO: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor symptoms, according to a study published online June 2 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Fatima Cardoso, M.D., from the Champalimaud Foundation in Lisbon, Portugal, and colleagues performed a phase 3 trial involving women aged 18 to 70 years with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer or its prevention.

Women were randomly assigned to receive once-daily elinzanetant at a dose of 120 mg for 52 weeks or once-daily placebo for 12 weeks followed by once-daily elinzanetant at a dose of 120 mg for 40 weeks (316 and 158 patients, respectively). Only one of the patients was taking endocrine therapy for breast cancer prevention.

The researchers found that the mean change from baseline in the mean daily frequency of moderate-to-severe vasomotor symptoms at week 4 was −6.5 and −3.0 episodes for those receiving elinzanetant and placebo, respectively (least-squares mean difference, −3.5 episodes). The mean change was −7.8 and −4.2 episodes among those receiving elinzanetant and placebo, respectively, at week 12 (least-squares mean difference, −3.4 episodes).

Overall, 69.8% and 62.0% of those receiving elinzanetant and placebo, respectively, reported at least one adverse event during weeks 1 through 12; serious adverse events occurred in 2.5% and 0.6%, respectively.

“In a finding consistent with the results of previous trials involving postmenopausal women, treatment with elinzanetant resulted in significant decreases in the frequency of vasomotor symptoms and in sleep disturbances and improvements in health-related quality of life among women with moderate-to-severe vasomotor symptoms taking endocrine therapy for breast cancer,” the authors write.

Several authors disclosed ties to Bayer, which is developing elinzanetant and funded the study.

More information:
Fatima Cardoso et al, Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2415566

Ann H. Partridge, Menopausal Symptom Management in Breast Cancer Survivors—A Promising New Option, New England Journal of Medicine (2025). DOI: 10.1056/NEJMe2506475

Copyright © 2025 HealthDay. All rights reserved.

Citation:
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy (2025, June 3)
retrieved 3 June 2025
from https://medicalxpress.com/news/2025-06-elinzanetant-vasomotor-symptoms-women-breast.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




ASCO: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor symptoms, according to a study published online June 2 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Fatima Cardoso, M.D., from the Champalimaud Foundation in Lisbon, Portugal, and colleagues performed a phase 3 trial involving women aged 18 to 70 years with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer or its prevention.

Women were randomly assigned to receive once-daily elinzanetant at a dose of 120 mg for 52 weeks or once-daily placebo for 12 weeks followed by once-daily elinzanetant at a dose of 120 mg for 40 weeks (316 and 158 patients, respectively). Only one of the patients was taking endocrine therapy for breast cancer prevention.

The researchers found that the mean change from baseline in the mean daily frequency of moderate-to-severe vasomotor symptoms at week 4 was −6.5 and −3.0 episodes for those receiving elinzanetant and placebo, respectively (least-squares mean difference, −3.5 episodes). The mean change was −7.8 and −4.2 episodes among those receiving elinzanetant and placebo, respectively, at week 12 (least-squares mean difference, −3.4 episodes).

Overall, 69.8% and 62.0% of those receiving elinzanetant and placebo, respectively, reported at least one adverse event during weeks 1 through 12; serious adverse events occurred in 2.5% and 0.6%, respectively.

“In a finding consistent with the results of previous trials involving postmenopausal women, treatment with elinzanetant resulted in significant decreases in the frequency of vasomotor symptoms and in sleep disturbances and improvements in health-related quality of life among women with moderate-to-severe vasomotor symptoms taking endocrine therapy for breast cancer,” the authors write.

Several authors disclosed ties to Bayer, which is developing elinzanetant and funded the study.

More information:
Fatima Cardoso et al, Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2415566

Ann H. Partridge, Menopausal Symptom Management in Breast Cancer Survivors—A Promising New Option, New England Journal of Medicine (2025). DOI: 10.1056/NEJMe2506475

Copyright © 2025 HealthDay. All rights reserved.

Citation:
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy (2025, June 3)
retrieved 3 June 2025
from https://medicalxpress.com/news/2025-06-elinzanetant-vasomotor-symptoms-women-breast.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Bakersfield girl who faced deportation and loss of lifesaving medical care is allowed to stay in U.S.

Next Post

Commercial space companies to fund launch range upgrades under $4 billion contract

Related Posts

FBI Asks Public for Tips on Medical Institutions Providing Gender-Affirming Surgeries on Kids

June 5, 2025
4
Emerging technologies in healthcare, part 2: General Catalyst

Emerging technologies in healthcare, part 2: General Catalyst

June 5, 2025
6
Next Post

Commercial space companies to fund launch range upgrades under $4 billion contract

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Rear view of a man wearing a cowboy hat looking over the debris of a tornado in the neighborhood of Sunshine Hills on May 17, 2025 in London, Kentucky

New NWS Hires Won’t Make Up for Trump Cuts, Meteorologists Say todayheadline

June 5, 2025

Dan Kerry: It’s time to get serious about protecting Canada’s arctic

June 5, 2025
The UK’s ‘Net Zero Straitjacket’: Crushing Costs And Wishful Thinking

The UK’s ‘Net Zero Straitjacket’: Crushing Costs And Wishful Thinking

June 5, 2025
Trashing Ontario’s Blue Box Regulations Will Reverse Progress on Waste Reduction

Trashing Ontario’s Blue Box Regulations Will Reverse Progress on Waste Reduction

June 5, 2025

Recent News

Rear view of a man wearing a cowboy hat looking over the debris of a tornado in the neighborhood of Sunshine Hills on May 17, 2025 in London, Kentucky

New NWS Hires Won’t Make Up for Trump Cuts, Meteorologists Say todayheadline

June 5, 2025
1

Dan Kerry: It’s time to get serious about protecting Canada’s arctic

June 5, 2025
2
The UK’s ‘Net Zero Straitjacket’: Crushing Costs And Wishful Thinking

The UK’s ‘Net Zero Straitjacket’: Crushing Costs And Wishful Thinking

June 5, 2025
4
Trashing Ontario’s Blue Box Regulations Will Reverse Progress on Waste Reduction

Trashing Ontario’s Blue Box Regulations Will Reverse Progress on Waste Reduction

June 5, 2025
4

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Rear view of a man wearing a cowboy hat looking over the debris of a tornado in the neighborhood of Sunshine Hills on May 17, 2025 in London, Kentucky

New NWS Hires Won’t Make Up for Trump Cuts, Meteorologists Say todayheadline

June 5, 2025

Dan Kerry: It’s time to get serious about protecting Canada’s arctic

June 5, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co